EpiPen alternative Symjepi gets FDA OK
The FDA has approved a new allergic reaction medication that could provide an alternative to Mylan’s EpiPen. Adamis Pharmaceuticals’ Symjepi comes as two pre-filled syringes of epinephrine and is indicated for Type 1 allergic reactions. The company plans to launch Symjepi in the second half of 2017 and is also preparing to create a junior version.
With its anticipated lower cost, smaller size and user-friendly design, Symjepi could be attractive for both patients and professionals according to CEO Dennis Carlo.
